

Anthony G Wilson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9505729/publications.pdf>

Version: 2024-02-01

65
papers

3,554
citations

236612

25
h-index

168136

53
g-index

67
all docs

67
docs citations

67
times ranked

6357
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010, 42, 508-514.	9.4	1,132
2	A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. <i>European Journal of Immunology</i> , 1994, 24, 191-195.	1.6	212
3	Epigenetic Regulation of Gene Expression in the Inflammatory Response and Relevance to Common Diseases. <i>Journal of Periodontology</i> , 2008, 79, 1514-1519.	1.7	186
4	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	1.5	146
5	Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. <i>Arthritis and Rheumatism</i> , 2011, 63, 645-653.	6.7	143
6	Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1645.	3.8	119
7	Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis. <i>Rheumatology</i> , 2010, 49, 2140-2146.	0.9	114
8	TNF2, a polymorphism of the tumour necrosis- β gene promoter, is a component of the celiac disease major histocompatibility complex haplotype. <i>European Journal of Immunology</i> , 1996, 26, 2113-2118.	1.6	100
9	Rheumatoid arthritis risk allele <i>PTPRC</i> is also associated with response to anti-tumor necrosis factor β therapy. <i>Arthritis and Rheumatism</i> , 2010, 62, 1849-1861.	6.7	95
10	Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. <i>Arthritis Research and Therapy</i> , 2010, 12, R175.	1.6	92
11	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Rheumatology</i> , 2015, 54, 494-499.	0.9	90
12	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	2.9	90
13	The Genetics of Generalized Osteoarthritis (GOGO) study: study design and evaluation of osteoarthritis phenotypes. <i>Osteoarthritis and Cartilage</i> , 2007, 15, 120-127.	0.6	89
14	Genetic and epigenetic predictors of responsiveness to treatment in RA. <i>Nature Reviews Rheumatology</i> , 2014, 10, 329-337.	3.5	78
15	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF- κ B signalling pathways. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1315-1320.	0.5	74
16	Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 861-868.	1.5	71
17	A candidate gene analysis of three related photosensitivity disorders: cutaneous lupus erythematosus, polymorphic light eruption and actinic prurigo. <i>British Journal of Dermatology</i> , 2001, 145, 229-236.	1.4	65
18	Replication of association of the <i>PTPRC</i> gene with response to anti-tumor necrosis factor therapy in a large UK cohort. <i>Arthritis and Rheumatism</i> , 2012, 64, 665-670.	6.7	65

#	ARTICLE	IF	CITATIONS
19	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1353-1360.	2.9	59
20	Facilitating public and patient involvement in basic and preclinical health research. <i>PLoS ONE</i> , 2019, 14, e0216600.	1.1	54
21	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 208-213.	0.5	49
22	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1364-1371.	0.9	43
23	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2018, 18, 657-664.	0.9	41
24	Interleukin 1 receptor antagonist (<i>IL1RN</i>) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 400-407.	0.5	35
25	Functional characterization of NF- κ B inhibitor-like protein 1 (NF κ BIL1), a candidate susceptibility gene for rheumatoid arthritis. <i>Human Molecular Genetics</i> , 2007, 16, 3027-3036.	1.4	28
26	Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis. <i>Human Molecular Genetics</i> , 2015, 24, 5367-5377.	1.4	27
27	C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11618-11623.	3.3	26
28	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and <i>CD39</i> . <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1055-1061.	0.5	25
29	Allele dose association of the C5orf30rs26232 variant with joint damage in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, n/a-n/a.	6.7	20
30	A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, R108.	1.6	19
31	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015, 385, S48.	6.3	18
32	A Novel <i>RELA</i> Truncating Mutation in a Familial Behçet's Disease-like Mucocutaneous Ulcerative Condition. <i>Arthritis and Rheumatology</i> , 2021, 73, 490-497.	2.9	16
33	Renegotiating dimensions of the self: A systematic review and qualitative evidence synthesis of the lived experience of self-managing rheumatoid arthritis. <i>Health Expectations</i> , 2020, 23, 1388-1411.	1.1	15
34	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. <i>Rheumatology</i> , 2016, 55, 2050-2055.	0.9	14
35	Variability in phenotype and response to treatment in chronic nonbacterial osteomyelitis; the Irish experience of a national cohort. <i>Pediatric Rheumatology</i> , 2021, 19, 45.	0.9	13
36	The Autoimmune Susceptibility Gene C5orf30 Regulates Macrophage-Mediated Resolution of Inflammation. <i>Journal of Immunology</i> , 2019, 202, 1069-1078.	0.4	12

#	ARTICLE	IF	CITATIONS
37	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. <i>Arthritis Research and Therapy</i> , 2021, 23, 80.	1.6	11
38	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. <i>Rheumatology</i> , 2017, 56, kew387.	0.9	10
39	Previously reported <i>SLCO1C1</i> genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. <i>Pharmacogenomics</i> , 2016, 17, 715-720.	0.6	9
40	Latent Class Trajectory Modeling of Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs. <i>Arthritis and Rheumatology</i> , 2020, 72, 1632-1642.	2.9	9
41	Can machine learning predict responses to TNF inhibitors?. <i>Nature Reviews Rheumatology</i> , 2019, 15, 702-704.	3.5	7
42	Patient and public involvement in biomedical research: training is not a substitute for relationship building. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1607-1608.	0.5	6
43	Resolving the Interactome of the Human Macrophage Immunometabolism Regulator (MACIR) with Enhanced Membrane Protein Preparation and Affinity Proteomics. <i>Proteomics</i> , 2020, 20, e2000062.	1.3	4
44	Cell-specific epigenetic drivers of pathogenesis in rheumatoid arthritis. <i>Epigenomics</i> , 2021, 13, 549-560.	1.0	4
45	The role of genetic analysis for predicting outcome of rheumatoid arthritis. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 809-814.	1.5	3
46	Association of the Rheumatoid Arthritis Severity Variant rs26232 with the Invasive Activity of Synovial Fibroblasts. <i>Cells</i> , 2019, 8, 1300.	1.8	3
47	Genetics of chronic nonbacterial osteomyelitis in the Irish population: no significant association with rare <i>FBLIM1</i> variants. <i>Pediatric Rheumatology</i> , 2021, 19, 32.	0.9	3
48	Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. <i>Pharmacogenomics</i> , 2020, 21, 1151-1156.	0.6	3
49	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy. <i>Rheumatology</i> , 2022, 61, 4935-4944.	0.9	3
50	Effects of a Tumour Necrosis Factor (TNF) Promoter Base Transition on Transcriptional Activity. <i>Clinical Science</i> , 1994, 87, 31P-31P.	0.0	1
51	(In)Visible illness: A photovoice study of the lived experience of self-managing rheumatoid arthritis. <i>PLoS ONE</i> , 2021, 16, e0248151.	1.1	1
52	P189: A longitudinal study of psychological predictors of response to adalimumab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	1
53	Tibiofemoral knee osteoarthritis progresses symmetrically by knee compartment in the GOGO cohort. <i>Osteoarthritis and Cartilage Open</i> , 2022, 4, 100288.	0.9	1
54	THU0020...Predicting Response to the Anti-Tnf Biologic, Etanercept in Rheumatoid Arthritis Patients Using Microrna Expression Profiling. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 200.1-200.	0.5	0

#	ARTICLE	IF	CITATIONS
55	O49.â€fPersonalized Genetic Medicine: Amino Acid Positions 11, 71 and 74 in HLA-DRB1 Predict Disease Severity, Mortality and Treatment Response in Rheumatoid Arthritisâ€”Multi-Centre Prospective Cohort Studies. Rheumatology, 2015, , .	0.9	0
56	O50â€fHigh Frequency of Anti-Drug Antibodies and Correlation of Low Random Drug Levels with Lack of Efficacy in Certolizumab Pegol-Treated Patients with Rheumatoid Arthritis. Rheumatology, 0, , .	0.9	0
57	A6.17â€f...FCGR2Aassociation with susceptibility to autoimmune and inflammatory diseases. Annals of the Rheumatic Diseases, 2016, 75, A54.2-A55.	0.5	0
58	SAT0018â€f...Preliminary Analysis Reveals An Interferon Signature Is Associated with Non-Response To Etanercept in Rheumatoid Arthritis Patients. Annals of the Rheumatic Diseases, 2016, 75, 670.1-670.	0.5	0
59	OP0236â€f...Whole Transcriptome Investigation of Response To Anti-TNF Treatment in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 147.2-147.	0.5	0
60	THU0002â€f...Etanercept and adalimumab exhibit heterogeneous early signatures of response in rheumatoid arthritis therapy. , 2017, , .		0
61	THU0001â€f...Differential methylation as a potential biomarker of methotrexate response in patients with rheumatoid arthritis. , 2017, , .		0
62	THU0001â€f...Differential methylation as a predictor of methotrexate response in patients with rheumatoid arthritis. , 2018, , .		0
63	P200â€fCombining protein quantitative trait and genetic risk score analysis to identify biomarkers of treatment response to TNFi in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
64	OA24â€fPredicting drug immunogenicity to tumour necrosis factor inhibitors in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	0.9	0
65	OA16â€fTherapeutic certolizumab pegol drug levels to achieve good EULAR response in patients with rheumatoid arthritis: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) cohort. Rheumatology, 2022, 61, .	0.9	0